Clinical trials: Deficiency Disease
HIV Infections
Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults
The purpose of this study is to evaluate the safety of and immune response to an alphavirus replicon, HIV-1 subtype C gag vaccine, AVX101, in HIV uninfected adults in the United States, South Africa, and Botswana.
- Trial name
- NCT00097838
- Testing
- AVX101
- Where
- 8 sites in United States, Botswana and 1 more
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
HIV Infections, Acquired Immunodeficiency Syndrome
An Expanded Safety Study of Dapivirine Gel 4759 in Africa
The purpose of this study is to determine whether dapivirine gel 4759 is safe for daily use by healthy women in Kenya, Malawi, Rwanda, South Africa and Tanzania.
- Trial name
- NCT00917891
- Testing
- dapivirine
- Where
- 10 sites in Kenya, Malawi and 3 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Acute Hepatic Porphyria, Hepatic Porphyrias
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic…
- Conditions
- Acute Hepatic Porphyria, Hepatic Porphyrias, Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP)
- Trial name
- NCT03547297
- Where
- 12 sites in United States
- Volunteers
- 212 people
- Sponsor
- Alnylam Pharmaceuticals
HIV Infections
A Study of MKC-442 in HIV-Positive Patients
The purpose of this study is to see if it is safe and effective to give MKC-442 plus at least two other anti-HIV drugs to patients who have never been treated with nonnucleoside reverse transcriptase inhibitors but who have been…
- Trial name
- NCT00002413
- Testing
- Emivirine
- Sponsor
- Triangle Pharmaceuticals
Primary Immunodeficiency
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
The purpose of this study is to demonstrate bioequivalence of IVIG-PEG with Gamunex-C (IVIG-C) at steady-state as determined by comparing total Immunoglobulin G (IgG) area under the concentration-time curve during the defined…
- Trial name
- NCT04561115
- Testing
- Gamunex-C, IVIG-PEG
- Where
- 10 sites in United States
- Volunteers
- 33 people
- Sponsor
- Grifols Therapeutics LLC
HIV Infections
A Pharmacokinetic Study of Dapivirine Vaginal Rings in Belgium
IPM 018 is a double-blind, randomized, placebo-controlled study conducted at one site in Belgium among 24 healthy, HIV-negative women to evaluate dapivirine release for 28 days from matrix and reservoir intravaginal rings, each…
- Trial name
- NCT00469768
- Testing
- dapivirine reservoir intravaginal ring, dapivirine matrix intravaginal ring
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections, Chickenpox
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
- Trial name
- NCT00002315
- Testing
- Netivudine, Acyclovir
- Where
- 25 sites in United States
- Volunteers
- 400 people
- Sponsor
- Glaxo Wellcome
Growth Hormone Deficiency
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD).
- Trial name
- OraGrowtH211 (NCT05796440)
- Testing
- LUM-201
- Where
- 7 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Lumos Pharma
Infection, Human Immunodeficiency Virus, HIV Infections
Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men
Studies to assess the effectiveness of interventions to prevent HIV infection depend upon robust estimates of Baseline HIV incidence rates.
- Trial name
- NCT03310515
- Testing
- Risk reduction counseling, Social harm interview, Computer-Assisted Self Interviewing technique
- Where
- 9 sites in China
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
The purpose of this study is to compare the safety and effectiveness of emtricitabine and stavudine when given with didanosine plus efavirenz to HIV-infected patients.
- Trial name
- NCT00006208
- Testing
- Efavirenz, Emtricitabine, Stavudine
- Where
- 63 sites in United States, Argentina and 4 more
- Sponsor
- Triangle Pharmaceuticals
Human Immunodeficiency Virus
Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women
Phase 1 PK Study of the Dapivirine Vaginal Ring in Lactating Women.
- Trial name
- NCT02808949
- Testing
- Dapivirine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Alpha1-Antitrypsin Deficiency
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
This is a multi-center, open-label study to evaluate the long-term safety of weekly intravenous (IV) infusions of 60 mg/kg alpha1-PI (human), modified process (Alpha-1 MP) in adult participants with Alpha1 Antitrypsin Deficiency…
- Trial name
- NCT02870348
- Testing
- Alpha-1 MP
- Where
- 3 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Grifols Therapeutics LLC
Sarcoma, Kaposi, HIV Infections
SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment
The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00005931
- Testing
- SU5416
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- SUGEN
Laxity; Skin, Volume Deficiency in the Mid-Face
Prospective Clinical Evaluation of the Safety and Performance of the Aesthetic Medical Device MEC REGENERATE® (Injectable Recombinant Collagen-based Product)
Prospective, spontaneous, open-label pre-market clinical trial with a single injection session; monitoring visits at baseline and 60 days post-treatment.
- Conditions
- Laxity; Skin, Volume Deficiency in the Mid-Face, Wrinkles
- Trial name
- NCT07413445
- Testing
- Treatment with experimental device
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- 303 Pharma s.r.l.
Infections, Human Immunodeficiency Virus and Hepatitis
Relative Bioavailability Study of GSK1265744 Formulations
This is a single-center, randomized, open-label, balanced, 3 way crossover study (3 periods) in healthy adult subjects. During each period, subjects will receive a single dose of GSK1265744 oral formulation in the fasted state…
- Trial name
- NCT01648257
- Testing
- GSK1265744 Na Salt Tablets, GSK1265744 Free Acid Nanomilled Capsules, GSK1265744 Free Acid Micronized Capsules
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments
The purpose of this study is to see if the addition of capravirine to VIRACEPT (nelfinavir mesylate) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is an effective combination drug therapy for HIV patients who have…
- Trial name
- NCT00006211
- Testing
- Capravirine, Nelfinavir mesylate
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Agouron Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ chronic…
- Trial name
- NCT02722304
- Testing
- ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- Baxalta now part of Shire
Epithelial Ovarian Cancer
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with…
- Trial name
- TREVI-OC-02 (NCT07851025)
- Testing
- Torvutatug samrotecan, Bevacizumab
- Where
- 186 sites in United States, Argentina and 22 more
- Volunteers
- 950 people
- Sponsor
- AstraZeneca
HIV Infections
Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers
Metabolic changes commonly occur in HIV therapy. The purpose of this study is to assess the impact on insulin sensitivity from the administration of tenofovir disoproxil fumarate 300 mg compared with placebo in non-HIV-1 infected…
- Trial name
- NCT00648817
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Fabry Disease
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
This is the first human treatment with PRX-102, an enzyme being developed as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha galactosidase deficiency).
- Trial name
- NCT01678898
- Testing
- PRX-102
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 18 people
- Sponsor
- Protalix